keyword
MENU ▼
Read by QxMD icon Read
search

Cachexia-anorexia cancer

keyword
https://www.readbyqxmd.com/read/29216311/amelioration-of-sexual-behavior-and-motor-activity-deficits-in-a-castrated-rodent-model-with-a-selective-androgen-receptor-modulator-sarm-2f
#1
Megumi Morimoto, Yuichiro Amano, Masahiro Oka, Ayako Harada, Hisashi Fujita, Yukiko Hikichi, Ryuichi Tozawa, Masuo Yamaoka, Takahito Hara
Sarcopenia and cachexia present characteristic features of a decrease in skeletal muscle mass and strength, anorexia, and lack of motivation. Treatments for these diseases have not yet been established, although selective androgen receptor modulators (SARMs) are considered as therapeutic targets. We previously reported that a novel SARM compound, SARM-2f, exhibits anabolic effect on muscles, with less stimulatory effect on prostate weight compared with testosterone, in rat Hershberger assays and cancer cachexia models...
2017: PloS One
https://www.readbyqxmd.com/read/29205286/anamorelin-ono-7643-for-the-treatment-of-patients-with-non-small-cell-lung-cancer-and-cachexia-results-from-a-randomized-double-blind-placebo-controlled-multicenter-study-of-japanese-patients-ono-7643-04
#2
Nobuyuki Katakami, Junji Uchino, Takuma Yokoyama, Tateaki Naito, Masashi Kondo, Kouzo Yamada, Hiromoto Kitajima, Kozo Yoshimori, Kazuhiro Sato, Hiroshi Saito, Keisuke Aoe, Tetsuya Tsuji, Yuichi Takiguchi, Koichi Takayama, Naoyuki Komura, Toru Takiguchi, Kenji Eguchi
BACKGROUND: Cachexia, described as weight loss (mainly in lean body mass [LBM]) and anorexia, is common in patients with advanced cancer. This study examined the efficacy and safety of anamorelin (ONO-7643), a novel selective ghrelin receptor agonist, in Japanese cancer patients with cachexia. METHODS: This double-blind clinical trial (ONO-7643-04) enrolled 174 patients with unresectable stage III/IV non-small cell lung cancer (NSCLC) and cachexia in Japan. Patients were randomized to daily oral anamorelin (100 mg) or a placebo for 12 weeks...
December 4, 2017: Cancer
https://www.readbyqxmd.com/read/29191597/anamorelin-for-advanced-non-small-cell-lung-cancer-with-cachexia-systematic-review-and-meta-analysis
#3
Kenichi Nishie, Shuhei Yamamoto, Chie Nagata, Tomonobu Koizumi, Masayuki Hanaoka
INTRODUCTION: Cancer anorexia-cachexia syndrome (CACS) is characterized by involuntary weight loss. CACS is commonly observed in advanced non-small-cell lung cancer (NSCLC), and it leads to a poor quality of life (QOL). No effective standard treatment exists for this condition. However, anamorelin has reportedly caused improvement in patients with several cancers. MATERIALS AND METHODS: We conducted a quantitative meta-analysis to explore the efficacy of anamorelin for treating CACS in patients with NSCLC...
October 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29165098/effects-of-olive-oil-on-tnf-%C3%AE-and-il-6-in-humans-implication-in-obesity-and-frailty
#4
Nagendra Sastry Yarla, Angela Polito, Ilaria Peluso
BACKGROUND AND OBJECTIVE: Tumor necrosis factor-alpha (TNF)-α and interleukin (IL)-6 are important mediators of chronic low-grade systemic inflammation. The latter plays a central role in several obesity-related pathologies, such as diabetes, metabolic syndrome and cardiovascular diseases. Besides, these cytokines have been also implicated in geriatric and cancer-induced anorexia, cachexia, sarcopenia and frailty. Potential interventions for both obesity and frailty include dietary advice and nutraceuticals...
November 20, 2017: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/29129392/targeting-obesity-and-cachexia-identification-of-the-gfral-receptor-mic-1-gdf15-pathway
#5
Samuel N Breit, Vicky Wang-Wei Tsai, David A Brown
Macrophage inhibitory cytokine-1/growth differentiation factor 15 (MIC-1/GDF15) is a divergent transforming growth factor (TGFβ) superfamily cytokine implicated in biological and disease processes including metabolism, cancer, and chronic inflammation, but whose receptor has remained elusive. Four laboratories have recently identified GFRAL, an orphan receptor of the glial-derived neurotrophic factor (GDNF) receptor α family, as the receptor for MIC-1/GDF15, signaling though the coreceptor Ret. These data identify a new systemic to central nervous system (CNS) circuit that regulates metabolism in response to stress and which could be targeted to treat both severe obesity and anorexia/cachexia syndrome...
November 9, 2017: Trends in Molecular Medicine
https://www.readbyqxmd.com/read/29108370/prevalence-of-malnutrition-in-patients-at-first-medical-oncology-visit-the-premio-study
#6
Maurizio Muscaritoli, Simone Lucia, Alessio Farcomeni, Vito Lorusso, Valeria Saracino, Carlo Barone, Francesca Plastino, Stefania Gori, Roberto Magarotto, Giacomo Carteni, Bruno Chiurazzi, Ida Pavese, Luca Marchetti, Vittorina Zagonel, Eleonora Bergo, Giuseppe Tonini, Marco Imperatori, Carmelo Iacono, Luigi Maiorana, Carmine Pinto, Daniela Rubino, Luigi Cavanna, Roberto Di Cicilia, Teresa Gamucci, Silvia Quadrini, Salvatore Palazzo, Stefano Minardi, Marco Merlano, Giuseppe Colucci, Paolo Marchetti
Background: In cancer patients, malnutrition is associated with treatment toxicity, complications, reduced physical functioning, and decreased survival. The Prevalence of Malnutrition in Oncology (PreMiO) study identified malnutrition or its risk among cancer patients making their first medical oncology visit. Innovatively, oncologists, not nutritionists, evaluated the nutritional status of the patients in this study. Methods: PreMiO was a prospective, observational study conducted at 22 medical oncology centers across Italy...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29095656/fabrication-of-eudragit-polymeric-nanoparticles-using-ultrasonic-nebulization-method-for-enhanced-oral-absorption-of-megestrol-acetate
#7
Seo Young Dai, Su-Eon Jin, Daehyun Kim, Don Haeng Lee, Su-Geun Yang
Megestrol acetate (MGA) is used as a progestagen to treat advanced cancers in the breast or uterus and anorexia-cachexia syndrome in cancer patients. Due to its low solubility (BCS class II), MGA bioavailability needs to be enhanced for efficacy and safety. We developed MGA-encapsulated Eudragit(®) L100 (EUD) nanoparticles (MGA-EUD (1:1) and MGA-EUD (2:1)) using an ultrasonic nebulization method. MGA-EUD (1:1) and MGA-EUD (2:1) consisted of MGA and EUD at the mass ratios of 1:1 and 2:1. Their physicochemical properties, i...
November 2, 2017: Pharmaceutical Development and Technology
https://www.readbyqxmd.com/read/29047408/the-efficacy-of-the-kampo-medicine-rikkunshito-for-chemotherapy-induced-anorexia-rich-trial-study-protocol-for-a-randomized-controlled-trial
#8
Takuya Inoue, Hironori Takagi, Yuki Owada, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroshi Yokouchi, Kenya Kanazawa, Katsuya Ohbuchi, Takahisa Fukushima, Mitsuru Munakata, Hiroyuki Suzuki
BACKGROUND: Cisplatin is a key drug in lung cancer therapy. However, cisplatin is also well known to induce gastrointestinal disorders, such as chemotherapy-induced nausea and vomiting, anorexia, and weight loss. These symptoms sometimes affect patients' quality of life and make continuation of chemotherapy difficult. Anorexia is a cause of concern for patients with cancer because a persistent loss of appetite progresses to cancer cachexia. Although evidence-based management for chemotherapy has recently been established, there is room for improvement...
October 18, 2017: Trials
https://www.readbyqxmd.com/read/29027398/nutritional-status-cachexia-and-anorexia-in-women-with-peritoneal-metastasis-and-intraperitoneal-chemotherapy-a-longitudinal-analysis
#9
Ziad Hilal, Günther A Rezniczek, Robert Klenke, Askin Dogan, Clemens B Tempfer
OBJECTIVE: To describe the nutritional status of women with peritoneal metastasis (PM) from recurrent ovarian, fallopian, or peritoneal cancer and to assess longitudinal variations of the cachexia-anorexia syndrome (CAS) during palliative pressurized intraperitoneal aerosol chemotherapy (PIPAC). METHODS: Nutritional assessment included body mass index (BMI), bioelectrical impedance analysis (BIA), and blood chemistry. CAS presence/absence was recorded before and during repeated cycles (1-11) of PIPAC...
November 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29019951/chemotherapy-related-toxicity-nutritional-status-and-quality-of-life-in-precachectic-oncologic-patients-with-or-without-high-protein-nutritional-support-a-prospective-randomized-study
#10
Monika Ziętarska, Joanna Krawczyk-Lipiec, Leszek Kraj, Renata Zaucha, Sylwia Małgorzewicz
BACKGROUND: Cancer disease is usually associated with impaired nutritional status, which is one of the factors contributing to deterioration of the results of surgery, chemotherapy or radiotherapy. OBJECTIVES: The aim of the study was to determine whether nutritional support with high protein (ONS) in adult oncologic patients in the first step of cancer cachexia-asymptomatic precachexia, has an influence on the toxicity of systemic therapy. However, secondary endpoints were established: to determine whether high protein ONS influences the nutritional status, the quality of life, and the performance status...
October 11, 2017: Nutrients
https://www.readbyqxmd.com/read/28957883/what-is-next-after-anamorelin
#11
Jose M Garcia
PURPOSE OF REVIEW: In spite of its relevance, treatments for the cancer anorexia and cachexia syndrome (CACS) are not available. One of the agents that recently reached phase III clinical trials is anamorelin. Its development, along with that of other agents for this indication, will be reviewed here, with a focus on the gaps in the current knowledge and future directions. RECENT FINDINGS: In spite of several targets showing promising results in early development, their difficulties obtaining regulatory approval underscore the need to reconsider the current strategies in drug development and the challenges in the field of CACS...
December 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28948436/mapping-health-related-quality-of-life-scores-from-fact-g-faact-and-facit-f-onto-preference-based-eq-5d-5l-utilities-in-non-small-cell-lung-cancer-cachexia
#12
Michela Meregaglia, Ludovica Borsoi, John Cairns, Rosanna Tarricone
BACKGROUND: Health-related quality of life (HRQoL) measurements from disease-specific tools cannot be directly used in economic evaluations. This study aimed to develop and validate mapping algorithms that predicted EuroQol 5-Dimensions 5-Levels (EQ-5D-5L) utilities from Functional Assessment of Anorexia-Cachexia Therapy (FAACT) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and their common component (Functional Assessment of Cancer Therapy-General-FACT-G) in patients with non-small cell lung cancer cachexia...
September 25, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28883883/atractylodin-induces-myosin-light-chain-phosphorylation-and-promotes-gastric-emptying-through-ghrelin-receptor
#13
Yu Bai, Yan-Hua Zhao, Jian-Ya Xu, Xi-Zhong Yu, Yun-Xia Hu, Zhi-Qiang Zhao
Atractylodin is one of the main constituents in the rhizomes of Atractylodes lancea Thunb., being capable of treating cancer cachexia-anorexia and age-related diseases as an agonist of growth hormone secretagogue receptor (GHSR). GHSR was herein expressed in human gastric smooth muscle cells (HGSMCs) and activated by ghrelin receptor agonist L-692,585. Like L-692,585, atractylodin also increased Ca(2+) and enhanced the phosphorylation of myosin light chain (MLC) through GHSR in HGSMCs. In addition, atractylodin promoted gastric emptying and MLC phosphorylation in the gastric antrum of mice also through GHSR...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/28858429/energy-imbalance-and-cancer-cause-or-consequence
#14
REVIEW
Xiaohui Wang, Wei Liu, Xiangyang Xie
Obesity has been an epidemic worldwide over the past decades and significantly increases the risk of developing a variety of deadly diseases including type 2 diabetes, cardiovascular diseases and many cancers. The relationship between obesity and type 2 diabetes and cardiovascular disease has been well documented. The drastically increased frequency of a number of cancers in obesity has attracted growing interest. On one hand, how increased adiposity promotes cancer development remains poorly understood, despite the fact that considerable epidemiological evidence has suggested links between them...
October 2017: IUBMB Life
https://www.readbyqxmd.com/read/28855797/oncology-update-anamorelin
#15
REVIEW
Eric Prommer
BACKGROUND: Cancer cachexia is a catabolic syndrome associated with uncontrolled muscle breakdown. There may be associated fat loss. Occurring in high frequency in advanced cancer, it is an indicator of poor prognosis. Besides weight loss, patients experience a cluster of symptoms including anorexia, early satiety, and weakness. The 3 stages of cachexia include stages of precachexia, cachexia, and refractory cachexia. Refractory cachexia is associated with active catabolism or the presence of factors that make active management of weight loss no longer possible...
2017: Palliative Care
https://www.readbyqxmd.com/read/28825869/cancer-cachexia-cause-diagnosis-and-treatment
#16
Todd W Mattox
Patients with cancer frequently experience unintended weight loss due to gastrointestinal (GI) dysfunction caused by the malignancy or treatment of the malignancy. However, others may present with weight loss related to other symptoms not clearly associated with identifiable GI dysfunction such as anorexia and early satiety. Cancer cachexia (CC) is a multifactorial syndrome that is generally characterized by ongoing loss of skeletal muscle mass with or without fat loss, often accompanied by anorexia, weakness, and fatigue...
October 2017: Nutrition in Clinical Practice
https://www.readbyqxmd.com/read/28751550/novel-targeted-therapies-for-cancer-cachexia
#17
REVIEW
Josep M Argilés, Francisco Javier López-Soriano, Britta Stemmler, Sílvia Busquets
Anorexia and metabolic alterations are the main components of the cachectic syndrome. Glucose intolerance, fat depletion, muscle protein catabolism and other alterations are involved in the development of cancer cachexia, a multi-organ syndrome. Nutritional approach strategies are not satisfactory in reversing the cachectic syndrome. The aim of the present review is to deal with the recent therapeutic targeted approaches that have been designed to fight and counteract wasting in cancer patients. Indeed, some promising targeted therapeutic approaches include ghrelin agonists, selective androgen receptor agonists, β-blockers and antimyostatin peptides...
July 27, 2017: Biochemical Journal
https://www.readbyqxmd.com/read/28708669/the-role-of-hypothalamic-inflammation-the-hypothalamic-pituitary-adrenal-axis-and-serotonin-in-the-cancer-anorexia-cachexia-syndrome
#18
Klaske van Norren, Jvalini T Dwarkasing, Renger F Witkamp
PURPOSE OF REVIEW: In cancer patients, the development of cachexia (muscle wasting) is frequently aggravated by anorexia (loss of appetite). Their concurrence is often referred to as anorexia-cachexia syndrome. This review focusses on the recent evidence underlining hypothalamic inflammation as key driver of these processes. Special attention is given to the involvement of hypothalamic serotonin. RECENT FINDINGS: The anorexia-cachexia syndrome is directly associated with higher mortality in cancer patients...
September 2017: Current Opinion in Clinical Nutrition and Metabolic Care
https://www.readbyqxmd.com/read/28691536/mabp1-for-the-treatment-of-colorectal-cancer
#19
Geraldine O'Sullivan Coyne, Mauricio Burotto
Inflammation is an established process in colorectal cancer development and a hallmark of progression, and pro-inflammatory cytokines have been implicated in the morbidity and functional compromise associated with malignancy. MABp1, described as a first-in-class true human antibody against interleukin-1α, has undergone clinical trial evaluation in a number of indications, recently completing late phase clinical trial testing under Fast Track designation for cancer anorexia-cachexia syndrome in colorectal cancer patients...
July 10, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28627024/the-applicability-of-a-weight-loss-grading-system-in-cancer-cachexia-a-longitudinal-analysis
#20
Ola Magne Vagnildhaug, David Blum, Andrew Wilcock, Peter Fayers, Florian Strasser, Vickie E Baracos, Marianne J Hjermstad, Stein Kaasa, Barry Laird, Tora S Solheim
BACKGROUND: A body mass index (BMI) adjusted weight loss grading system (WLGS) is related to survival in patients with cancer. The aim of this study was to examine the applicability of the WLGS by confirming its prognostic validity, evaluating its relationship to cachexia domains, and exploring its ability to predict cachexia progression. METHODS: An international, prospective observational study of patients with incurable cancer was conducted. For each patient, weight loss grade was scored 0-4...
October 2017: Journal of Cachexia, Sarcopenia and Muscle
keyword
keyword
103177
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"